[Clinical study of carumonam].

Abstract

To evaluate the clinical efficacy of carumonam (CRMN, AMA-1080), the drug was used in the treatment of 10 patients including 4 with pneumonia and each with acute tonsillitis, chronic bronchitis, Mycoplasma pneumonia, primary atypical pneumonia (PAP), chronic pyelitis, and acute cystitis. Since beta-lactam antibiotics were not active against Mycoplasma pneumonia and PAP, these diseases were excluded from the clinical efficacy evaluation of CRMN. Responses were excellent in 1 patient and good in 7. Side effects were not observed. The laboratory test recognized slight elevations of GOT, GPT and eosinophilia in 1 patient and a slight leucopenia in another upon the administration of CRMN.

• Authors: K Takebe, T Tamura, K Endo, T Irie, K Sekino, O Uehara, M Sagara, K Okamoto
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 40 Issue 11 Pg. 1917-22 (Nov 1987) ISSN: 0368-2781 [Print] Japan
• PMID: 3444030 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Lactams
• carumonam
• Aztreonam

Topics

• Adult
• Aged
• Anti-Bacterial Agents (administration & dosage, therapeutic use)
• Aztreonam (analogs & derivatives)
• Bacterial Infections (drug therapy)
• Female
• Humans
• Infusions, Intravenous
• Lactams
• Male
• Middle Aged
• Respiratory Tract Infections (drug therapy)